loader2
Partner With Us NRI

Indoco Remedies Ltd share Price Today

Company details

327.45
338.80
306.40
415.00
6M Return -1.72%
1Y Return -2.20%
Mkt Cap.(Cr) 3,028.51
Volume 75,404
Div Yield 0.68%
OI
-
OI Chg %
-
Volume 75,404

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
About The Stock

    Indoco manufactures and markets branded formulations and APIs for the domestic and export markets. In domestic formulations, through its nine marketing divisions, the company serves a range of specialties.

    • Domestic formulations accounted for 54% of revenues. Major therapies are: respiratory, anti-infectives, stomatologicals, gastrointestinals and vitamins
    • Formulation exports accounted for 41% (regulated markets:81%) of revenues while APIs contributed 4% with remaining coming from CRAMS
Q4FY22

    Indoco reported robust revenue growth in both domestic (up 39% YoY to ₹ 193 crore) and export formulations (up 44% YoY to ₹ 190 crore)

    • Sales were up 34% YoY to ₹ 409 crore
    • EBITDA was at ₹ 81 crore, up 47% YoY with margins at 19.7%
    • PAT for Q4 was at ₹ 40 crore (up 62% YoY)

Click here for full recommendation

Research view on more stocks

Pharmaceuticals firm Indoco Remedies announced Q3FY24 results:

Q3FY24

  • Revenue:
    Rs 4,484 million (growth of 9.2% compared to Rs 4,106 million in Q3 of the previous year)
  • EBIDTA:
    Rs 653 million, representing 14.6% of net sales (compared to Rs 617 million or 15.0% of net sales in Q3 of the previous year)
  • Profit After Tax:
    Rs 282 million (before exceptional item), which is comparable to the profit of Rs 279 million reported in the same quarter last year

9MFY24 (Apr-Dec)

  • Revenue:
    Rs 13,268 million (9.6% increase from Rs 12,101 million in the same period last year)
  • EBIDTA:
    Rs 2,006 million, 15.1% of net sales (against Rs 2,207 million, 18.2% of net sales in the previous year)
  • Profit After Tax:
    Rs 873 million (before exceptional item), 6.6% of net sales (compared to 9.6% or Rs 1,160 million in the same period last year)

Aditi Panandikar, Managing Director of Indoco Remedies Ltd., stated: "Our Q3 performance is primarily driven by International business particularly US and Emerging Markets, API business and steady performance by India business."

 

 

Result PDF

View Other Company Results

Indoco Remedies Ltd shares SWOT Analysis

Strengths (5)

  • Company with Low Debt
  • Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
  • Book Value per share Improving for last 2 years

Weakness (3)

  • Declining Net Cash Flow : Companies not able to generate net cash
  • Major fall in TTM Net Profit
  • Weak Momentum: Price below Short, Medium and Long Term Averages

Opportunity (0)

Data not found

Threats (1)

  • RSI indicating price weakness

Resistance and support

R1 335.8
R2 343.0
R3 347.2
Pivot

331.63

S1 324.5
S2 320.3
S3 313.1
EMA SMA
338.4
350.2
354.4
353.0
337.1
354.5
363.9
346.7
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
XTX MARKETS LLP Bulk Purchase 2021-08-12 507.94 478901 NSE
XTX MARKETS LLP Bulk Sell 2021-08-12 508.51 481713 NSE
DOVETAIL INDIA FUND CLASS 6 SHARES Bulk Purchase 2020-12-02 265.31 500000 NSE
Name Category Shares
PANANDIKAR ADITI MILIND PROMOTER 6.07%
MADHURA SURESH KARE PROMOTER 5.64%
KARE ARUNA SURESH PROMOTER 5.2%
KARE SURESH GOVIND PROMOTER 4.41%
SPA HOLDINGS PVT LTD PROMOTER 19.9%
SHANTERI INVESTMENT PVT LTD PROMOTER 17.12%

OUR RESEARCH VIEW

Investment recommendation
Call Date
25 Jan 2023
Entry Price 348.00
Target Price 440.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Indoco Remedies Ltd Stocks COMPARISON

Financials( in Cr) Indoco Remedies Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Dr Reddys Laboratories Ltd Zydus Lifesciences Ltd
Price 328.65 1,620.55 1,496.95 6,157.90 1,007.35
% Change -1.57 1.02 2.30 1.88 0.77
Mcap Cr 3,028.51 388,824.23 120,856.26 102,719.31 101,964.37
Revenue TTM Cr 1,668.61 43,885.68 15,790.60 24,669.70 17,237.40
Net Profit TTM Cr 142.25 8,560.84 2,513.47 4,507.30 1,997.30
PE TTM 28.22 41.45 30.52 19.64 30.51
1 Year Return -2.20 64.78 68.33 37.28 109.04
ROCE 16.74 16.79 14.76 25.99 16.25
ROE 14.72 16.46 10.66 21.21 14.05
INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 1,028.25 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 29,068.81 33,709.58
LAST 3M 68,518.10 30,558.15
LAST 6M 130,081.93 64,349.19
LAST 12M 189,941.35 208,211.24
Indoco Remedies Limited - Trading Window

Mar 28, 2024 l NSE Announcement

Warren Remedies commences commercial production of its greenfield units at Aurangabad

Mar 26, 2024 l BSE Announcement

Date Action Type Ratio
Sep 18, 2023 Dividend 112.5
Sep 14, 2022 Dividend 37.5
Sep 14, 2022 Dividend 75

Indoco Remedies Ltd Information

Stock PE (TTM)
28.22
Promoter Holding
58.74%
Book Value
115.9344
ROCE
16.74%
ROE
14.72%
Description
  • Indoco Remedies Ltd. is a fully integrated, research-oriented pharma company. It manufactures and markets Active Pharmaceutical Ingredients (APIs) and Formulations (Finished Dosage Forms). It was incorporated in 1947, with its headquarters in Mumbai. During FY 2021-2022, the company generated a total revenue of Rs 1,543.08 crore, up 23.98% from the previous financial year, 2020-2021. On 31 October 2022, Indoco Remedies Ltd.’s market capitalisation was Rs 3,262 crore.

    The company is listed on the Bombay Stock Exchange with the code 532612, and on the National Stock Exchange with the code INDOCO. It is also listed on the MCX Stock Exchange.

    Indoco Remedies Ltd. has a well-built brand portfolio with a number of products in various therapeutic segments. It includes high-growth lifestyle segments like cardiovascular, musculoskeletal, anti-diabetics, central nervous system, dental care, and nutrition. The company has a strong presence in the international market across 55 countries and employs close to 6000 personnel with more than 300 skilled scientists. It has nine manufacturing facilities, of which three are for APIs and six for finished dosages.

    On 30 June 2022, the company’s shareholding pattern showed a promoter holding of 58.69%, an FII holding of 1.17%, a DII holding of 18.08%, and a public holding of 22.06%. The leading promoter is Spa Holdings Pvt Ltd., with a 19.9% share. In the June 2022 quarter, mutual fund holdings decreased from 17.52% to 17.39%, while FPI holdings increased from 1.15% to 1.17%.

    The company’s board of directors comprises Mr Suresh G Kare, Mr Sundeep V Bambolkar, Mr Rajiv P Kakodkar, Dr Anand Nadkarni, Mr D M Gavaskar, Mr Abhijit Yashwant Gore, Dr (Ms) Vasudha V Kamat, and Ms Aditi Kare Panandikar. The auditors are Gokhale & Sathe. As of 30 June 2022, the company’s total outstanding shares were 9.22 crores.

    On 31 October 2022, the company’s share’s closing price was Rs 353.60 on BSE. On NSE, its closing price was Rs 354. The share touched a 52-week high of Rs 498 and a 52-week low of Rs 307.65. Investors earned a six-month return of -8.63% and a one-year return of -21.40%.

    The company’s peers include Sun Pharmaceuticals Industries Ltd., Cipla Ltd., Dr Reddys Laboratories Ltd., and Divis Laboratories Ltd.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

Indoco House 166 C S T Road, Santacruz (East) Kalina, Mumbai, Maharashtra, 400098

Tel : 91-022-26541851-55
Email : compliance.officer:indoco.com
Website : http://www.indoco.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 532612
NSE Code : INDOCO
Book Closure Date (Month) : Sep
BSE Group : A
ISIN : INE873D01024

FAQ’s on Indoco Remedies Ltd Shares

You can buy Indoco Remedies Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Indoco Remedies Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Mar 28, 2024 03:54 PM the closing price of Indoco Remedies Ltd was ₹ 328.65.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Mar 28, 2024 03:54 PM, the market cap of Indoco Remedies Ltd stood at ₹ 3,028.51.

The latest PE ratio of Indoco Remedies Ltd as of Mar 28, 2024 03:54 PM is 28.22

The latest PB ratio of Indoco Remedies Ltd as of Mar 28, 2024 03:54 PM is 0.35

The 52-week high of Indoco Remedies Ltd share price is ₹ 415.00 while the 52-week low is ₹ 306.40

According to analyst recommendations, Indoco Remedies Ltd Share has a “Buy” rating for the long term.

Download Our

Download App
market app